Targeted binding agents against B7-H1
Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
1. An isolated antibody or fragment thereof that specifically binds to B7-H1, wherein the antibody or fragment thereof comprises:
a VH CDR1 consisting of the amino acid sequence of SEQ ID NO: 3,
a VH CDR2 consisting of the amino acid sequence of SEQ ID NO: 4,
a VH CDR3 consisting of the amino acid sequence of SEQ ID NO: 5,
a VL CDR1 consisting of the amino acid sequence of SEQ ID NO: 8,
a VL CDR2 consisting of the amino acid sequence of SEQ ID NO: 9, and
a VL CDR3 consisting of the amino acid sequence of SEQ ID NO: 10; or
a VH CDR1 consisting of the amino acid sequence of SEQ ID NO: 63,
a VH CDR2 consisting of the amino acid sequence of SEQ ID NO: 64,
a VH CDR3 consisting of the amino acid sequence of SEQ ID NO: 65,
a VL CDR1 consisting of the amino acid sequence of SEQ ID NO: 68,
a VL CDR2 consisting of the amino acid sequence of SEQ ID NO: 69, and
a VL CDR3 consisting of the amino acid sequence of SEQ ID NO: 70.
2. The antibody or fragment thereof of claim 1 , wherein the antibody is a monoclonal antibody.
3. The antibody or fragment thereof of claim 2 , wherein the antibody is a fully human monoclonal antibody.
4. The antibody or fragment thereof according to any one of the preceding claims, wherein the antibody or fragment thereof comprises a heavy chain variable domain consisting of the amino acid sequence of SEQ ID NO: 2 and a light chain variable domain consisting of the amino acid sequence of SEQ ID NO: 7; or a heavy chain variable domain consisting of the amino acid sequence of SEQ ID NO: 62 and a light chain variable domain consisting of the amino acid sequence of SEQ ID NO: 67.
5. The antibody or fragment thereof of claim 4 , wherein the fragment is a binding fragment selected from the group consisting of a Fab, Fab′, F(ab′)2, Fv and dAb fragment.
6. The antibody or fragment thereof of claim 4 , wherein the Fc region of the antibody is characterized by the residues of 234F, 235E, and 331S, as numbered by the EU index as set forth in Kabat.
7. A nucleic acid molecule encoding the antibody of claim 1 .
8. An isolated host cell transfected with a vector comprising the nucleic acid molecule of claim 7 .
9. An antibody produced by a method comprising, culturing the host cell of claim 8 , expressing an antibody encoded by the nucleic acid molecule of claim 7 , and isolating the antibody from the culture.
10. A composition comprising the antibody of claim 1 .
11. A pharmaceutical composition comprising the antibody of claim 1 and pharmaceutically acceptable carrier.